No Data
No Data
Investor Optimism Abounds Bluebird Bio, Inc. (NASDAQ:BLUE) But Growth Is Lacking
Bluebird Bio Trading Halted, News Pending
Express News | Trading Halt: Halted at 7:50:00 P.m. ET - Trading Halt: Halt News Pending
Bluebird Bio To Carry Out 1-for-20 Reverse Stock Split On December 13th, 2024
Reported Sunday, Bluebird Bio Highlights 9-Year Data For LYFGENIA Gene Therapy: Sustained Benefits In Sickle Cell Disease Patients At ASH 2024
Bluebird Bio Announced Long-Term Follow-Up Data Continue To Support Beti-Cel As Potentially Curative Gene Therapy For Β-Thalassemia Patients Who Require Regular Transfusions Through Achievement Of Durable Transfusion Independence And Normal Or...
Unlock the Full List